Novo Nordisk Pre-Tax Profit Margin 2010-2024 | NVO

Current and historical pre-tax profit margin for Novo Nordisk (NVO) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Novo Nordisk pre-tax profit margin for the three months ending September 30, 2024 was .
Novo Nordisk Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2024-09-30 $39.37B $17.36B 44.10%
2024-06-30 $37.44B $16.39B 43.79%
2024-03-31 $35.55B $16.28B 45.80%
2023-12-31 $33.72B $15.20B 45.07%
2023-09-30 $30.85B $13.44B 43.57%
2023-06-30 $28.44B $11.79B 41.44%
2023-03-31 $26.41B $10.64B 40.30%
2022-12-31 $25.06B $9.78B 39.03%
2022-09-30 $24.32B $9.55B 39.25%
2022-06-30 $23.81B $9.50B 39.92%
2022-03-31 $23.26B $9.52B 40.92%
2021-12-31 $22.40B $9.40B 41.96%
2021-09-30 $21.64B $9.35B 43.18%
2021-06-30 $20.85B $8.94B 42.88%
2021-03-31 $19.93B $8.51B 42.69%
2020-12-31 $19.45B $8.14B 41.86%
2020-09-30 $19.09B $7.83B 41.00%
2020-06-30 $18.74B $7.64B 40.75%
2020-03-31 $18.84B $7.49B 39.74%
2019-12-31 $18.29B $7.28B 39.79%
2019-09-30 $17.43B $6.94B 39.83%
2019-06-30 $17.25B $6.87B 39.86%
2019-03-31 $17.11B $7.05B 41.18%
2018-12-31 $17.10B $7.28B 42.58%
2018-09-30 $17.61B $7.68B 43.59%
2018-06-30 $17.49B $7.91B 45.23%
2018-03-31 $17.33B $7.78B 44.87%
2017-12-31 $16.97B $7.40B 43.58%
2017-09-30 $16.81B $7.28B 43.32%
2017-06-30 $16.73B $7.16B 42.77%
2017-03-31 $16.67B $7.20B 43.20%
2016-12-31 $16.61B $7.10B 42.76%
2016-09-30 $16.56B $7.03B 42.45%
2016-06-30 $16.43B $6.70B 40.77%
2016-03-31 $16.26B $6.35B 39.01%
2015-12-31 $16.06B $6.47B 40.29%
2015-09-30 $15.99B $6.36B 39.81%
2015-06-30 $15.95B $6.36B 39.86%
2015-03-31 $15.92B $6.45B 40.51%
2014-12-31 $15.83B $6.08B 38.39%
2014-09-30 $15.63B $6.11B 39.07%
2014-06-30 $15.31B $6.08B 39.67%
2014-03-31 $15.08B $5.94B 39.41%
2013-12-31 $14.89B $5.80B 38.93%
2013-09-30 $14.58B $5.67B 38.90%
2013-06-30 $14.27B $5.44B 38.08%
2013-03-31 $13.89B $5.11B 36.81%
2012-12-31 $13.48B $4.81B 35.64%
2012-09-30 $13.04B $4.56B 34.97%
2012-06-30 $12.80B $4.36B 34.07%
2012-03-31 $12.52B $4.20B 33.51%
2011-12-31 $12.27B $4.10B 33.40%
2011-09-30 $12.04B $3.91B 32.46%
2011-06-30 $11.85B $3.68B 31.02%
2011-03-31 $11.48B $3.43B 29.85%
2010-12-31 $11.06B $3.26B 29.49%
2010-09-30 $10.66B $3.00B 28.13%
2010-06-30 $10.24B $2.89B 28.20%
2010-03-31 $9.90B $2.81B 28.39%
2009-12-31 $9.67B $2.62B 27.09%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $460.555B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94